Trial site
Clinic Of Pulmonology Semmelweis University
Budapest Viii, 1083, HungaryEU-13 widening countryNot linked to an institution yet
- 18running trials
- 8closed trials
The trials here
What the 26 trials at this site are about, from their registry records.
- Phase
- Phase 315 trials
- Phase 29 trials
- Phase 2/32 trials
- Status
- Recruiting10 trials
- Completed8 trials
- Active, not recruiting5 trials
- Not yet recruiting3 trials
- Lead sponsor
- Merck Sharp & Dohme LLC3 trials
- AstraZeneca2 trials
- Boehringer Ingelheim2 trials
- Bristol-Myers Squibb2 trials
- Bristol-Myers Squibb Services Unlimited Company2 trials
- and 15 more
Running trials
Not yet recruiting
Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis
NCT07441408· Phase 3· Bristol-Myers Squibb· Source
Not yet recruiting
A Randomized, Double-Blind, Placebo-controlled, Parallel Arm, 52-week Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of Two Doses of EXPD-101 in Participants with COPD
2026-525216-34-00· Phase 2· Expedition Therapeutics Inc.· Source
Recruiting
A Phase IIb Study to Evaluate AZD8965 in Participants with Idiopathic Pulmonary Fibrosis (IPF)
2025-525016-41-00· Phase 2· AstraZeneca AB· Source
Recruiting
A Study to Evaluate the Efficacy and Safety of Once Daily Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Arterial Hypertension (PAH)
NCT07481981· Phase 3· Insmed Incorporated· Source
Recruiting
Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer
NCT07288177· Phase 2· Genmab· Source
Recruiting
Study of ABBV-142 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Idiopathic Pulmonary Fibrosis
NCT07230288· Phase 2· AbbVie· Source
Recruiting
A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
NCT07063745· Phase 2/3· Bristol-Myers Squibb· Source
Recruiting
A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-1)
NCT07276724· Phase 3· Generate Biomedicines· Source
Recruiting
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
NCT07291037· Phase 3· AstraZeneca· Source
Recruiting
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
NCT07064473· Phase 3· Boehringer Ingelheim· Source
Active, not recruiting
A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-031/LIGHTRAY EXTENSION)
NCT06925750· Phase 2· Merck Sharp & Dohme LLC· Source
Recruiting
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)
NCT06712316· Phase 2/3· BioNTech SE· Source
Recruiting
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
NCT06692738· Phase 3· AstraZeneca· Source
Recruiting
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis
2023-503699-25-00· Phase 3· Bristol-Myers Squibb Services Unlimited Company· Source
Recruiting
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants with Idiopathic Pulmonary Fibrosis
2023-503697-21-01· Phase 3· Bristol-Myers Squibb Services Unlimited Company· Source
Active, not recruiting
Clairleafᵀᴹ: A Study to Test Long-term Treatment With BI 1291583 in People With Bronchiectasis Who Took Part in a Previous Study With This Medicine
NCT05846230· Phase 2· Boehringer Ingelheim· Source
Recruiting
Roll Over StudY for Patients Who Have Completed a Previous Oncology Study with Durvalumab
NCT05303532· Phase 3· Astrazeneca AB· Source
Active, not recruiting
Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension
NCT04273945· Phase 3· Actelion· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error